Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.
Vaccine
; 41(21): 3337-3346, 2023 05 16.
Article
in English
| MEDLINE | ID: covidwho-2293136
ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks have constituted a public health issue with drastic mortality higher than 34%, necessitating the development of an effective vaccine. During MERS-CoV infection, the trimeric spike protein on the viral envelope is primarily responsible for attachment to host cellular receptor, dipeptidyl peptidase 4 (DPP4). With the goal of generating a protein-based prophylactic, we designed a subunit vaccine comprising the recombinant S1 protein with a trimerization motif (S1-Fd) and examined its immunogenicity and protective immune responses in combination with various adjuvants. We found that sera from immunized wild-type and human DPP4 transgenic mice contained S1-specific antibodies that can neutralize MERS-CoV infection in susceptible cells. Vaccination with S1-Fd protein in combination with a saponin-based QS-21 adjuvant provided long-term humoral as well as cellular immunity in mice. Our findings highlight the significance of the trimeric S1 protein in the development of MERS-CoV vaccines and offer a suitable adjuvant, QS-21, to induce robust and prolonged memory T cell response.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Coronavirus Infections
/
Middle East Respiratory Syndrome Coronavirus
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Vaccine
Year:
2023
Document Type:
Article
Affiliation country:
J.vaccine.2023.04.006
Similar
MEDLINE
...
LILACS
LIS